Nanopharmaceutical and Regulatory Science (McNeil)
Head of Research Unit
Prof. Dr.Scott McNeil
Publications
4 found
Show per page
Hemmrich, Eva and McNeil, Scott (2024) ‘Strategic aspects for the commercialization of nanomedicines’, Journal of Controlled Release, 369, pp. 617–621. Available at: https://doi.org/10.1016/j.jconrel.2024.04.003.
Hemmrich, Eva and McNeil, Scott (2024) ‘Strategic aspects for the commercialization of nanomedicines’, Journal of Controlled Release, 369, pp. 617–621. Available at: https://doi.org/10.1016/j.jconrel.2024.04.003.
Hemmrich, Eva and McNeil, Scott (2023) ‘Active ingredient vs excipient debate for nanomedicines’, Nature Nanotechnology, 18, pp. 692–695. Available at: https://doi.org/10.1038/s41565-023-01371-w.
Hemmrich, Eva and McNeil, Scott (2023) ‘Active ingredient vs excipient debate for nanomedicines’, Nature Nanotechnology, 18, pp. 692–695. Available at: https://doi.org/10.1038/s41565-023-01371-w.
Klein, Kevin et al. (2021) ‘A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways’, Annals of the New York Academy of Sciences, 1502, pp. 5–13. Available at: https://doi.org/10.1111/nyas.14662.
Klein, Kevin et al. (2021) ‘A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways’, Annals of the New York Academy of Sciences, 1502, pp. 5–13. Available at: https://doi.org/10.1111/nyas.14662.
Smith, Mackensie C et al. (2017) ‘Zeta potential: a case study of cationic, anionic, and neutral liposomes’, Analytical and bioanalytical chemistry, 409(24), pp. 5779–5787. Available at: https://doi.org/10.1007/s00216-017-0527-z.
Smith, Mackensie C et al. (2017) ‘Zeta potential: a case study of cationic, anionic, and neutral liposomes’, Analytical and bioanalytical chemistry, 409(24), pp. 5779–5787. Available at: https://doi.org/10.1007/s00216-017-0527-z.